Literature DB >> 15667230

Prescribing of antipsychotic medication in a medicaid population: use of polytherapy and off-label dosages.

Stephen J Kogut1, Felix Yam, Robert Dufresne.   

Abstract

OBJECTIVES: To describe the use of atypical antipsychotic medications in a Medicaid-enrolled population composed primarily of elderly and disabled patients. Our analyses focused upon the frequency of use of polytherapy with multiple antipsychotic medications and the prescribing of off-label dosages.
METHODS: We conducted a cross-sectional retrospective analysis of oral antipsychotic medication use, as prescribed for this population in 2003. The unit of analysis was the patient. We determined the prevalence of use of each type of antipsychotic medication according to gender and age group and determined the extent of use of combination therapies with multiple oral antipsychotic medications. Using the dosage ranges described in the product labeling, we identified the percentage of patients prescribed in-range dosages, overall and for each atypical antipsychotic medication studied. Those identified as receiving out-of-range (off-label) dosages were further stratified by gender and age group. The statistical significance of differences between these proportions was assessed using the chi-square test.
RESULTS: Of the 8,616 patients meeting our inclusion criteria, 7,748 (90%) received monotherapy with an oral antipsychotic medication and 868 patients (10%) received polytherapy with multiple oral antipsychotic medications. Approximately 2 of 3 patients receiving atypical antipsychotic medications were prescribed a dosage that was within the range recommended in the product labeling. Dosages lower than recommended in the product labeling were prescribed for 27% of patients receiving atypical antipsychotics, while 6% of patients received an above-range dosage. The frequency of patients receiving in-range dosages varied substantially among medications. Younger patients and male patients were more frequently prescribed above-range dosages while older patients and female patients were more frequently prescribed below-range dosages of these medications (P<0.001 for both findings).
CONCLUSION: In this subpopulation of Medicaid enrollees who were prescribed antipsychotic medications, we found a 10% incidence of use of antipsychotic polytherapy and a 33% incidence of prescribing of dosages outside the range listed in the product labeling. These findings suggest that physicians commonly prescribe antipsychotic medications in a manner that differs from the recommendations described in the prescribing information. The off-label use of atypical antipsychotic medications raises important questions regarding the purpose and applicability of the product labeling and the role and ability of the pharmacist to provide information regarding the risks and benefits of therapy as commonly prescribed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15667230     DOI: 10.18553/jmcp.2005.11.1.17

Source DB:  PubMed          Journal:  J Manag Care Pharm        ISSN: 1083-4087


  14 in total

Review 1.  Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research.

Authors:  Nasra Haroun; Laura Dunn; Ansar Haroun; Kristin S Cadenhead
Journal:  Schizophr Bull       Date:  2005-10-05       Impact factor: 9.306

Review 2.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

3.  Antipsychotic Medication Use Among Publicly Insured Pregnant Women in the United States.

Authors:  Yoonyoung Park; Krista F Huybrechts; Jacqueline M Cohen; Brian T Bateman; Rishi J Desai; Elisabetta Patorno; Helen Mogun; Lee S Cohen; Sonia Hernandez-Diaz
Journal:  Psychiatr Serv       Date:  2017-06-15       Impact factor: 3.084

4.  The QTc interval and its dispersion in patients receiving two atypical antipsychotics.

Authors:  Christoph U Correll; Anne M Frederickson; Vicki Figen; Elizabeth J Ginn-Scott; Rudy A Pantaleon Moya; John M Kane; Peter Manu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06-20       Impact factor: 5.270

Review 5.  A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Authors:  William G Honer; Ric M Procyshyn; Eric Y H Chen; G William MacEwan; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

Review 6.  Atypical antipsychotic-induced metabolic disturbances in the elderly.

Authors:  Melanie Dawn Guenette; Araba Chintoh; Gary Remington; Margaret Hahn
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

7.  Polypharmacy in the management of patients with schizophrenia on risperidone in a tertiary-care hospital in Malaysia.

Authors:  Sa Jacob; Mi Mohamed Ibrahim; F Mohammed
Journal:  Ment Health Fam Med       Date:  2013-01

8.  Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization.

Authors:  Shannon N Saldaña; Brooks R Keeshin; Anna M Wehry; Thomas J Blom; Michael T Sorter; Melissa P DelBello; Jeffrey R Strawn
Journal:  Pharmacotherapy       Date:  2014-07-03       Impact factor: 4.705

9.  Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges.

Authors:  Stephen Crystal; Mark Olfson; Cecilia Huang; Harold Pincus; Tobias Gerhard
Journal:  Health Aff (Millwood)       Date:  2009-07-21       Impact factor: 6.301

Review 10.  Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment.

Authors:  Nitin Toteja; Juan A Gallego; Ema Saito; Tobias Gerhard; Almut Winterstein; Mark Olfson; Christoph U Correll
Journal:  Int J Neuropsychopharmacol       Date:  2013-05-14       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.